eligibility_summary
Adults 18–69 with relapsed/refractory B‑ALL (incl Ph+ after/intolerant to ≥2 TKIs), B‑cell NHL or HL. CAR cohorts: anti‑CD19 for CD19+ ALL or specified NHL (e.g., DLBCL, PMBCL, TFL, MCL, HGBL, CLL/SLL), anti‑CD20/30 for prior CD20/30 CAR or dual CD20/CD30+, anti‑CD30 for CD30+ HL or T‑cell lymphoma. Need ECOG≤2, ≥12‑wk survival, adequate labs/organ function. Exclude active CNS disease, uncontrolled infection, viral seropositivity, major cardiac/autoimmune/GVHD, recent prohibited therapy, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Early phase, single-center, open-label study of autologous CAR T-cell therapy in relapsed/refractory hematologic malignancies. Interventions: anti-CD19 CAR T (CD19+ ALL/NHL), anti-CD30 CAR T (CD30+ Hodgkin or T-cell lymphoma), and bispecific anti-CD20/CD30 CAR T (CD20+ or CD20/CD30 double-positive lymphoma, including post–CD19 CAR T relapse). Mechanism: patient T cells engineered with chimeric antigen receptors that bind CD19, CD20, and/or CD30, inducing MHC-independent T-cell activation, proliferation, cytokine release, and cytotoxic killing of target cells. Lymphodepletion: fludarabine (purine analog, DNA synthesis inhibitor) and cyclophosphamide (alkylator) to deplete host lymphocytes and enhance CAR T expansion. Targets/pathways: CD19/CD20 on malignant B cells, CD30 on HL and T-cell lymphoma.